Cutting Costs for CML Abroad

Cutting Costs for CML Abroad

By Ilana Yurkiewicz, MD “If you have to get cancer,” I once reassured a frightened patient, “CML [chronic myeloid leukemia] isn’t bad.” CML is truly one of our cancer success stories. The identification of a single genetic swap — BCR-ABL — and the development of...
The Roman God of Portals and More

The Roman God of Portals and More

By Binod Dhakal, MD, MS In 1951 a renowned hematologist from Harvard University, William Dameshek, MD, wrote an editorial in Blood providing seminal insight into myeloproliferative neoplasms (MPNs) — a group of disorders characterized by expansion of different myeloid...

One-Size-Fits-All for AML? Not Anymore

By Ilana Yurkiewicz, MD Once upon a time, there was “7+3.” Developed in the 1970s, this easy-to-remember induction chemotherapy regimen for acute myeloid leukemia (AML) went largely unchanged for decades. But in the past few years, we have seen multiple new drug...

I AM IRONMAN!

By Alexander K. Glaros, MD, and Ahmar U. Zaidi, MD If you’re a nerd like… Scratch that…If you’re in Orlando this week, it’s either because you have a favorite blood cell type (gotta be the sea blue histiocyte) or you still haven’t given up on your...

Blood Counts: Reducing the Burden of Red Blood Cell Transfusions

By Ahmar U. Zaidi, MD The first transfusions in the 19th century were rife with adverse events, poor outcomes, and even patient deaths. To no one’s surprise then, medical providers became dubious of this “dangerous” procedure. It was after Landsteiner and Jansky...

Constructing an Idea: From Wings to Landing Gear

By Janice Staber, MD “Great ideas need landing gear as well as wings.” — Charles Douglas Jackson In the Special-Interest Session, Systems-Based Hematology: How to Implement Evidence-Based Programs for Virtual Hematology Consults and Anticoagulation Stewardship, Michal...

Sunday’s Continuing Conversations With the Speakers

Continuing Conversations with the Speakers sessions allow for informal discussions with Scientific Program session speakers that will give interested individuals, especially trainees and junior investigators, increased accessibility both to information on the topic...

ASH Research Collaborative Sickle Cell Disease Clinical Trials Network

The ASH Research Collaborative (ASH RC) was established by ASH in 2018 with the goal of fostering collaborative partnerships to accelerate progress in hematology and improve lives of those affected by blood diseases. The ASH RC has two main components: the Data Hub...
Supporting Hematology’s Future: The ASH Scholar Award

Supporting Hematology’s Future: The ASH Scholar Award

The ASH Scholar Award is the Society’s longest-standing award program and one of the most highly regarded. For almost three decades, ASH has supported hundreds of fellows and junior faculty in both basic and clinical/translational research by providing partial salary...

ASH Practice Partnership Lunch Spotlights Genomic/Genetic Testing

The ASH Practice Partnership is the Society’s network of practice-based hematologists with interests in practice-related policies, quality of care, new health care delivery systems, and practice management issues. The ASH Practice Partnership Lunch is a special...